By Adria Calatayud Roche Holding has agreed to buy Telavant Holdings from Roivant Sciences and Pfizer in a deal worth up to $7.25 billion as the Swiss...
Roche Holding has agreed to buy Telavant Holdings from Roivant Sciences and Pfizer in a deal worth up to $7.25 billion as the Swiss pharmaceutical giant seeks to bolster its immunology pipeline.
The deal is the latest example of big pharma companies' renewed appetite for acquisitions. Roche's move comes after Rahway, N.J.-based Merck earlier this year bought Prometheus Biosciences, which is developing a drug for inflammatory bowel disease that would compete with Telavant's candidate, as part of a push into immune-disease treatments.
RVT-3101 is an antibody drug in development for people suffering from inflammatory bowel disease--a chronic gastrointestinal disorder--that has potential to be applied in multiple other diseases given that it targets both inflammation and fibrosis, Roche said.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Roche to Buy Telavant From Roivant Sciences and Pfizer in $7.25 Bln DealBy Adria Calatayud Roche Holding has agreed to buy Telavant Holdings from Roivant Sciences and Pfizer in a deal worth up to $7.25 billion that will give it...
Read more »
Roche to Buy Telavant from Roivant Sciences, Pfizer for $7.1 BillionIt will buy immunology company Telavant Holdings from Roivant Sciences and Pfizer.
Read more »
Swiss pharma giant Roche agrees $7.1 billion deal to buy Telavant HoldingsSwiss health care company Roche announced it would acquire Telavant Holdings Monday, in a deal worth $7.1 billion.
Read more »
Swiss pharma giant Roche agrees $7.1 billion deal to buy Telavant HoldingsSwiss health care company Roche announced it would acquire Telavant Holdings Monday, in a deal worth $7.1 billion.
Read more »
Roche buys Telavant Holdings for $7.1 billionRoche buys Telavant Holdings for $7.1 billion
Read more »
Stock movers: Hess, Chevron, Roivant Sciences, Harpoon TherapeuticsHess Corp. Harpoon Therapeutics, Chevron, Pfizer, Roivant Sciences and Great Ajax were on the move.
Read more »